Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTHNASDAQ:GRTXNASDAQ:ONCTNASDAQ:PLXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.18+8.6%$0.17$0.12▼$3.39$1.46M-0.05989,329 shs12,385 shsGRTXGalera Therapeutics$0.03-1.7%$0.03$0.02▼$0.15$2.15M1.8796,340 shs28,426 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.83$1.56M1.1885,229 shsN/APLXPPLx Pharma$0.00$0.02▼$0.04$603K3.7912.96 million shs3,000 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path+8.58%-8.15%-2.28%+13.48%-91.03%GRTXGalera Therapeutics-1.72%+1.79%+16.80%-12.31%-78.90%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-93.16%PLXPPLx Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path2.4742 of 5 stars3.55.00.00.00.00.01.3GRTXGalera Therapeutics0.2555 of 5 stars0.03.00.00.00.61.70.0ONCTOncternal TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path 3.00Buy$20.0011,270.10% UpsideGRTXGalera Therapeutics 0.00N/AN/AN/AONCTOncternal Therapeutics 2.25Hold$10.001,798.97% UpsidePLXPPLx Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/AGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05PLXPPLx Pharma$4.54M0.00N/AN/A$1.30 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%8/13/2025 (Estimated)GRTXGalera Therapeutics-$59.08M-$0.35N/A∞N/AN/AN/A-99.34%8/12/2025 (Estimated)ONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/APLXPPLx Pharma-$46.13M-$1.85N/AN/AN/A-606.91%-291.11%-119.43%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A0.860.86GRTXGalera TherapeuticsN/A9.749.74ONCTOncternal TherapeuticsN/A2.392.39PLXPPLx PharmaN/A4.794.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%GRTXGalera Therapeutics50.77%ONCTOncternal Therapeutics16.05%PLXPPLx Pharma21.19%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path0.72%GRTXGalera Therapeutics12.90%ONCTOncternal Therapeutics11.20%PLXPPLx Pharma8.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path108.31 million5.73 millionOptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableONCTOncternal Therapeutics302.96 million2.63 millionNo DataPLXPPLx Pharma1629.14 million26.53 millionNot OptionablePLXP, GRTX, ONCT, and BPTH HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Protalix (PLX)February 3, 2025 | markets.businessinsider.comGRAVITY Co (NASDAQ:GRVY) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comPLXp/USD - Pullix US DollarAugust 24, 2024 | investing.comProtalix Biotherapeutics Inc (PLX)January 30, 2024 | investing.comVertex Pharmaceuticals Inc VRTXJanuary 22, 2024 | morningstar.comMVietnam National Petroleum Group (PLX)October 23, 2023 | investing.comPLx Pharma Inc (PLXPQ)August 21, 2023 | uk.investing.comPharmaceutical R&D: the road to positive returnsJuly 16, 2023 | nature.comNPLXPQ PLx Pharma Inc.April 21, 2023 | seekingalpha.comPLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE(R) and Substantially All of its AssetsApril 13, 2023 | marketwatch.comWhy PLx Pharma Shares Are Nosediving TodayApril 12, 2023 | msn.comWhy iMedia Brands Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving PremarketApril 12, 2023 | msn.comWhy PLx Pharma Shares Are Down Over 40% TuesdayApril 11, 2023 | msn.comPLx Pharma Inc. Receives Nasdaq Delisting NoticeApril 11, 2023 | finance.yahoo.comShort Volatility Alert: Plx Pharma IncApril 11, 2023 | msn.comPLx Pharma's Return On Capital Employed InsightsDecember 22, 2022 | msn.comPLx Pharma (PLXP) Q3 2022 Earnings Call TranscriptNovember 11, 2022 | seekingalpha.comPLx Pharma down after Q3 revenue fell 94% Y/YNovember 11, 2022 | seekingalpha.comPLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business UpdateNovember 10, 2022 | finance.yahoo.comPLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue EstimatesNovember 10, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLXP, GRTX, ONCT, and BPTH Company DescriptionsBio-Path NASDAQ:BPTH$0.18 +0.01 (+8.58%) As of 06/27/2025 03:31 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Galera Therapeutics NASDAQ:GRTX$0.03 0.00 (-1.72%) As of 06/27/2025 03:18 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Oncternal Therapeutics NASDAQ:ONCT$0.53 0.00 (0.00%) As of 04/29/2025Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.PLx Pharma NASDAQ:PLXPPLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
